Special Issue

Innovations in Personalized Diagnosis and Treatment for Cystic Fibrosis

Message from the Guest Editor

Cystic fibrosis (CF) is a genetic disorder primarily affecting the respiratory and digestive systems. Since the discovery of the CFTR gene, the focus of CF research has evolved from symptom management to understanding the molecular basis of the disease, leading to more personalized approaches for diagnosis and treatment. CF serves as a prime example of how personalized medicine can be applied to genetic diseases, showcasing the potential for individualized diagnostic and therapeutic strategies. This Special Issue aims to explore the latest advances in personalized medicine for CF, including innovative diagnostic techniques, targeted therapies, and novel approaches for patient care that consider individual genetic and phenotypic differences. We are seeking the submission of cutting-edge research on CFTR modulators, gene therapy, and pharmacogenomics, as well as the development of new biomarkers for more precise diagnostics. In this Special Issue, original research articles and reviews are welcome to be submitted, particularly those that contribute new insights into personalized diagnosis, innovative treatment strategies, and the application of these findings to clinical practice.

Guest Editor

Dr. Martina Gentzsch
Marsico Lung Institute and Cystic Fibrosis Research Center, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

closed (22 May 2025)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/215432

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI